CLINICAL TRIAL: ADJUNCTIVE TREATMENT WITH DIVALPROEX OR RISPERIDONE FOR AGGRESSI

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目通过一项多点随机临床试验和双模拟药物给药，比较了利培酮和丙戊酸盐两种药物在减少注意缺陷多动障碍儿童的攻击行为方面的有效性、耐受性和持久性，当辅助使用兴奋剂治疗时，这些儿童对兴奋剂单一治疗和行为干预明显反应不足。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project compares, via a multisite, randomized clinical trial with double-dummy medication administration, the efficacy, tolerability, and longevity of benefit of two agents, risperidone and valproate, in diminishing aggressive behavior among children with attention deficit hyperactivity disorder when used adjunctively with stimulant treatment among children who experience demonstrably inadequate response to stimulant monotherapy and behavioral intervention.